|Bid||13.24 x 154300|
|Ask||13.25 x 392000|
|Day's Range||12.96 - 13.24|
|52 Week Range||8.70 - 14.49|
|PE Ratio (TTM)||44.13|
|Earnings Date||May 21, 2018 - May 25, 2018|
|Forward Dividend & Yield||0.16 (2.09%)|
|1y Target Est||12.37|
Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH), a medical equipment company based in New Zealand, saw significant share price volatility over the past couple of months on the NZSE, risingRead More...
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) has returned toRead More...
Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) delivered an ROE of 26.97% over the past 12 months, which is an impressive feat relative to its industry average of 12.29% duringRead More...
Companies such as Fisher & Paykel Healthcare and Gentrack Group have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolioRead More...
New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents. Fisher & Paykel said it was seeking a range of legal remedies from the lawsuit, including banning the manufacture and sale of such Resmed products in Australia. Fisher & Paykel and California-based Resmed are engaged in patent disputes in several countries over medical devices used to treat respiratory conditions.
New Zealand's Fisher & Paykel Healthcare (FPH.NZ) said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's (RMD.N) patent was invalid. Fisher & Paykel filed the case against California-based Resmed in Britain's High Court in 2016, and has similar legal proceedings underway in Germany, after Resmed had said the New Zealand company's masks violated Resmed patents. "This result confirms that UK patients can continue to purchase and enjoy the benefits of our high-performance masks," Fisher & Paykel said in a statement in which it announced the UK court ruling.
New Zealand's Fisher & Paykel Healthcare said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's patent was invalid. Fisher & Paykel filed the case against California-based Resmed in Britain's High Court in 2016, and has similar legal proceedings underway in Germany, after Resmed had said the New Zealand company's masks violated Resmed patents.
Fast-growing stocks may be appealing for some investors, whereas robust dividend-generating stocks may be more suitable for others. There are many different factors to deliberate on when deciding which investmentRead More...
Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as AFT Pharmaceuticals and Freightways are considered to be high growth in terms ofRead More...
A German court has suspended health appliance firm ResMed Inc's intellectual property proceedings against New Zealand's Fisher & Paykel Healthcare Corp, according to a statement from Fisher & Paykel. The court proceedings were suspended while both firms waited for the outcome of a European Patent Office decision over Resmed's patents, Fisher & Paykel said in a filing on Friday with New Zealand's stock exchange.
Preliminary 2017 Fisher & Paykel Healthcare Corporation Ltd Earnings Call
Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday. Fisher & Paykel Healthcare's shares rose as much as 4.8 percent after the announcement. ResMed lodged its complaint with the USITC last August, after filing court proceedings in multiple countries, asking the trade body to investigate and stop Fisher & Paykel importing its sleep masks into the United States.